Source Natural Foods & Herbal Supplements Ltd
Incorporated in 1998, Source Natural Foods and Herbal Supplements Ltd deals in ayurvedic products and green energy segment.[1]
- Market Cap ₹ 73.2 Cr.
- Current Price ₹ 114
- High / Low ₹ 170 / 96.6
- Stock P/E 20.9
- Book Value ₹ 40.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 14.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.54 | 10.93 | 15.94 | 10.84 | 12.81 | 13.59 | 24.88 | 21.53 | 19.79 | 27.30 | 44.92 | 70.38 | 79.70 | |
| 5.83 | 9.97 | 14.12 | 9.43 | 11.22 | 11.20 | 20.71 | 17.68 | 16.18 | 22.83 | 39.78 | 64.49 | 73.40 | |
| Operating Profit | 0.71 | 0.96 | 1.82 | 1.41 | 1.59 | 2.39 | 4.17 | 3.85 | 3.61 | 4.47 | 5.14 | 5.89 | 6.30 |
| OPM % | 10.86% | 8.78% | 11.42% | 13.01% | 12.41% | 17.59% | 16.76% | 17.88% | 18.24% | 16.37% | 11.44% | 8.37% | 7.90% |
| 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.33 | 0.49 | 0.01 | -0.04 | 0.08 | 0.06 | 0.23 | |
| Interest | 0.01 | 0.01 | 0.07 | 0.24 | 0.20 | 0.23 | 0.10 | 0.24 | 0.27 | 0.21 | 0.62 | 0.65 | 0.76 |
| Depreciation | 0.54 | 0.49 | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 | 0.42 | 0.62 | 1.04 | 1.02 | 0.38 | 0.72 |
| Profit before tax | 0.16 | 0.47 | 1.41 | 0.83 | 1.05 | 1.84 | 4.03 | 3.68 | 2.73 | 3.18 | 3.58 | 4.92 | 5.05 |
| Tax % | 0.00% | 10.64% | 0.71% | 3.61% | 2.86% | 11.41% | 16.38% | 33.97% | 22.71% | 45.28% | 18.99% | 30.89% | |
| 0.16 | 0.43 | 1.40 | 0.80 | 1.03 | 1.64 | 3.37 | 2.43 | 2.12 | 1.74 | 2.90 | 3.40 | 3.50 | |
| EPS in Rs | 0.26 | 0.67 | 2.17 | 1.24 | 1.60 | 2.55 | 5.24 | 3.78 | 3.29 | 2.70 | 4.51 | 5.28 | 5.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 62.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 23% |
| 3 Years: | 53% |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 0% |
| 3 Years: | 17% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -8% |
| 3 Years: | 8% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 13% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.10 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 |
| Reserves | -0.96 | -0.88 | 0.53 | 1.33 | 2.36 | 3.35 | 6.73 | 9.16 | 11.28 | 13.02 | 15.92 | 19.32 |
| 0.09 | 0.08 | 1.91 | 1.77 | 0.16 | 1.12 | 0.93 | 0.04 | 0.02 | 1.24 | 7.41 | 7.79 | |
| 0.77 | 0.98 | 2.63 | 1.56 | 1.84 | 2.23 | 3.13 | 3.69 | 3.96 | 4.18 | 6.06 | 7.38 | |
| Total Liabilities | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 35.83 | 40.93 |
| 3.66 | 3.31 | 3.53 | 3.58 | 3.57 | 3.31 | 3.88 | 5.00 | 6.56 | 5.52 | 4.59 | 4.16 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.34 | 3.31 | 7.98 | 7.52 | 7.23 | 9.83 | 13.01 | 14.33 | 15.14 | 19.36 | 31.24 | 36.77 | |
| Total Assets | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 35.83 | 40.93 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.38 | 0.38 | -0.69 | 0.11 | 2.64 | -0.36 | 4.46 | -0.70 | 2.51 | 2.69 | 0.07 | -2.49 | |
| -0.40 | -0.16 | -1.95 | 0.14 | -0.31 | -0.71 | -2.09 | 0.07 | 0.06 | 0.29 | -5.33 | -2.36 | |
| 0.11 | 0.01 | 2.06 | -0.42 | -1.60 | 0.32 | 0.32 | -1.20 | -0.53 | 1.19 | 5.40 | -0.17 | |
| Net Cash Flow | 0.08 | 0.23 | -0.58 | -0.18 | 0.74 | -0.74 | 2.69 | -1.83 | 2.04 | 4.18 | 0.13 | -5.01 |
| Free Cash Flow | -0.02 | 0.24 | -1.26 | -0.29 | 2.31 | -0.44 | 3.20 | -1.90 | 2.59 | 2.69 | -0.02 | -3.10 |
| CFO/OP | 54% | 40% | -38% | 8% | 166% | -15% | 107% | -18% | 70% | 60% | 1% | -42% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.84 | 27.72 | 100.52 | 139.06 | 94.88 | 182.37 | 87.88 | 131.22 | 136.67 | 100.41 | 99.46 | 92.68 |
| Inventory Days | 218.30 | 143.24 | 115.92 | 202.88 | 149.49 | 92.38 | 64.09 | 106.83 | 141.55 | 93.59 | 66.20 | 55.93 |
| Days Payable | 108.28 | 81.70 | 84.18 | 36.13 | 46.29 | 58.58 | 22.10 | 57.67 | 78.93 | 60.94 | 35.55 | 35.90 |
| Cash Conversion Cycle | 122.86 | 89.26 | 132.26 | 305.81 | 198.08 | 216.16 | 129.86 | 180.37 | 199.29 | 133.06 | 130.10 | 112.71 |
| Working Capital Days | 57.48 | 53.10 | 74.88 | 124.92 | 112.83 | 155.78 | 68.66 | 163.09 | 156.77 | 98.27 | 49.00 | 77.53 |
| ROCE % | 3.31% | 8.83% | 20.39% | 11.62% | 13.51% | 20.84% | 33.11% | 26.36% | 17.97% | 17.90% | 16.64% | 17.59% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Ayurvedic Medicines Share of Sale of Products % |
|
||||||||
| Number of Permanent Employees count |
|||||||||
| Ojasvita Share of Sale of Products % |
|||||||||
| Veg Capsules & Cookies Share of Sale of Products % |
|||||||||
| Power Consumption KWH |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication - Unaudited Financial results for the quarter ended June 30, 2026
-
Proposed Incorporation Of Wholly Owned Subsidiary
- Board approved incorporation of wholly owned subsidiary SN Solar Mangaluru Private Limited for solar PV projects.
-
Financial Results For The Quarter Ended 30Th June, 2026
- Board approved Q1 FY2026-27 results and proposed 1.782 MW rooftop solar project under RESCO/OPEX model.
-
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended June 30, 2026
- Board approved Q1 FY27 results and proposed 1.782 MW rooftop solar RESCO/OPEX project on August 10, 2026.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026
- Board to meet on August 10, 2026, to approve Q1 FY2027 unaudited results; trading window closed from July 1.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
SNFHSL is in the business of Ayurvedic Medicines and Foods Supplements segments.
The company is expanding its portfolios in green energy vertical and is also focusing on diversification into wastewater and solid waste
management.